Precision medicine in rheumatoid arthritis: unravelling sex-driven differences in response to treatment-Reference-Cited by-同舟云学术

Precision medicine in rheumatoid arthritis: unravelling sex-driven differences in response to treatment

Published:2022-10 Issue:10 Volume:4 Page:e650-e651
ISSN:2665-9913
Container-title:The Lancet Rheumatology
language:en
Short-container-title:The Lancet Rheumatology

Author:

Sepriano Alexandre,Nikiphorou Elena

Funder

Gilead Sciences

Eli Lilly and Company

Pfizer

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy,Rheumatology

Reference6 articles.

1. Sex differences in response to anti-tumor necrosis factor therapy in early and established rheumatoid arthritis—results from the DANBIO registry;Jawaheer;J Rheumatol,2012

2. Disease progression and treatment responses in a prospective DMARD-naive seropositive early rheumatoid arthritis cohort: does gender matter?;Jawaheer;J Rheumatol,2010

3. Sex differences in remission rates over 24 weeks among three different biological treatments compared to conventional therapy in patients with early rheumatoid arthritis (NORD-STAR): a post-hoc analysis of a randomised controlled trial;Lend;Lancet Rheumatol,2022

4. Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial;Hetland;BMJ,2020

5. The book of why: the new science of cause and effect;Pearl,2019

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biologics or Janus Kinase Inhibitors in Rheumatoid Arthritis Patients Who are Insufficient Responders to Conventional Anti-Rheumatic Drugs;Drugs;2024-07-01